Efficacy of combined adjuvant transarterial chemoembolization and antiviral therapy in patients with HBV-related hepatocellular carcinoma after surgery

We read with interest a recent retrospective study in Tumor Biology that reported that disease-free survival (DFS) and overall survival in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after surgery was significantly better when they received adjuvant transarterial che...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2015-09, Vol.36 (10), p.7395-7396
Main Authors: Ma, Song-Lin, Lv, Yang, Jiang, Jing-Hang
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Carcinoma, Hepatocellular - drug therapy
Chemoembolization, Therapeutic
Commentary
Female
Hepatitis B virus - pathogenicity
Humans
Liver Neoplasms - drug therapy
Male
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We read with interest a recent retrospective study in Tumor Biology that reported that disease-free survival (DFS) and overall survival in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after surgery was significantly better when they received adjuvant transarterial chemoembolization (TACE) and nucleos(t)ide analog (NA) therapy than when they received only TACE [1]. While we applaud the authors efforts to clarify the most effective HCC treatments, we feel their conclusions should be interpreted with caution, given that several characteristics of their study population may make it less representative of clinical reality.
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-015-4026-6